The antiphospholipid triangle.
Galli
M
M
Department of Hematology-Oncology, Ospedali Riuniti, Bergamo, Italy. monicagalli@ospedaliriuniti.bergamo.it
D000284:Administration, Oral; D017153:Antibodies, Anticardiolipin / Q000097:blood; D017152:Antibodies, Antiphospholipid / Q000097:blood*; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects; D016736:Antiphospholipid Syndrome / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology / Q000401:mortality; D015415:Biomarkers / Q000097:blood; D018450:Disease Progression; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D015994:Incidence; D016682:Lupus Coagulation Inhibitor / Q000097:blood; D011237:Predictive Value of Tests; D012008:Recurrence; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology / Q000401:mortality; D053482:beta 2-Glycoprotein I / Q000276:immunology
D017153:Antibodies, Anticardiolipin; D017152:Antibodies, Antiphospholipid; D000925:Anticoagulants; D015415:Biomarkers; D016682:Lupus Coagulation Inhibitor; D053482:beta 2-Glycoprotein I